![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
LIVER TRANSAMINASES LEVELS POST DEFERASIROX TREATMENT IN ?-THALASSEMIA MAJOR CHILDREN IN WESTERN MAHARASHTRA
Pravin D. Dhote*, Rajib Chatterjee and Jayashree Jadhav
ABSTRACT Objectives: This study was done to determine the extent of the effect of deferasirox therapy on liver transaminases levels in β-thalassemia major patients presenting to our setup. Material and Methods: It was a retrospective longitudinal observational study conducted at Pravara Rural Hospital, Ahmednagar, in November 2021. Thirty-five patients with β -thalassemia major were included in the study. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured on admission. The previous one-year record was obtained from the central pac system of the hospital. In addition, the patient taking deferasirox at 30 mg /kg/day dose were included whose previous record was available and were continuously on deferasirox therapy. Results: In comparison to mean baseline ALT values, there were significantly elevated mean ALT values after Deferasirox therapy. There was nearly eleven times relative risk of having ALT ≥ 5 upper normal levels (UNL) in a patient with abnormal baseline ALT (Odd ratio 10.96,95% Confidence Interval: lower 2.05, upper 58.58). During a year of study, Deferasirox therapy was associated with ALT readings of ≥ 5UNL in 22(31%) of pediatric β-thalassemia patients and that elevation lasted for four weeks in 95.5% of patients. Conclusions: Elevated ALT of ≥ 5UNL after Deferasirox therapy was short-lived and lasted for four weeks in 95.5% of patients. It is advisable to start Deferasirox therapy at a dose of 30 mg /kg/day when the baseline ALT level is normal. Keywords: Thalassemia, Deferasirox, liver transaminases, ALT, AST. [Download Article] [Download Certifiate] |